 This is an investigational study. Lenalidomide is approved by the Food and Drug Administration FDA and commercially available for the treatment of specific types of myelodysplastic syndrome MDS and in combination with dexamethasone for patients with multiple myeloma MM who have received at least 1 prior therapy. Paclitaxel is FDA-approved and commercially available for the treatment of bladder cancer, lung cancer, breast cancer, and pancreatic cancer. The use of these drugs in combination is investigational. 